MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

International Consensus Panel

doi:10.1053/j.gastro.2019.11.312

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

International Consensus Panel

Medicine, Hepatology Division

Research output: Contribution to journal › Article › peer-review

2108 Scopus citations

Abstract

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. Although pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge, and metabolic (dysfunction) associated fatty liver disease “MAFLD” was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and subphenotype the disease to accelerate the translational path to new treatments.

Original language	English (US)
Pages (from-to)	1999-2014.e1
Journal	Gastroenterology
Volume	158
Issue number	7
DOIs	https://doi.org/10.1053/j.gastro.2019.11.312
State	Published - May 2020

Funding

Funding Mohammed Eslam and Jacob George are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation , University of Sydney ; a National Health and Medical Research Council of Australia (NHMRC) Program Grant ( APP1053206 , APP1149976 ); and Project Grants ( APP1107178 and APP1108422 ). Philip N. Newsome, on the international consensus panel, is funded and supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the NHS. Funding Mohammed Eslam and Jacob George are supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney; a National Health and Medical Research Council of Australia (NHMRC) Program Grant (APP1053206, APP1149976); and Project Grants (APP1107178 and APP1108422). Philip N. Newsome, on the international consensus panel, is funded and supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the NHS.

Keywords

Heterogeneity
MAFLD
Metabolic
Nomenclature

ASJC Scopus subject areas

Gastroenterology
Hepatology

Access to Document

10.1053/j.gastro.2019.11.312

Cite this

@article{3b326ec0d79d41ba8fcc2b40ab90c7cf,

title = "MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease",

abstract = "Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. Although pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge, and metabolic (dysfunction) associated fatty liver disease “MAFLD” was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and subphenotype the disease to accelerate the translational path to new treatments.",

keywords = "Heterogeneity, MAFLD, Metabolic, Nomenclature",

author = "{International Consensus Panel} and Mohammed Eslam and Sanyal, {Arun J.} and Jacob George and Arun Sanyal and Brent Neuschwander-Tetri and Claudio Tiribelli and Kleiner, {David E.} and Elizabeth Brunt and Elisabetta Bugianesi and Hannele Yki-J{\"a}rvinen and Henning Gr{\o}nb{\ae}k and Helena Cortez-Pinto and Jiangao Fan and Luca Valenti and Manal Abdelmalek and Manuel Romero-Gomez and Mary Rinella and Marco Arrese and Pierre Bedossa and Newsome, {Philip N.} and Anstee, {Quentin M.} and Rajiv Jalan and Ramon Bataller and Rohit Loomba and Silvia Sookoian and Sarin, {Shiv K.} and Stephen Harrison and Takumi Kawaguchi and Wong, {Vincent Wai Sun} and Vlad Ratziu and Yusuf Yilmaz and Zobair Younossi",

note = "Publisher Copyright: {\textcopyright} 2020 AGA Institute",

year = "2020",

month = may,

doi = "10.1053/j.gastro.2019.11.312",

language = "English (US)",

volume = "158",

pages = "1999--2014.e1",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "7",

}

TY - JOUR

T1 - MAFLD

T2 - A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

AU - International Consensus Panel

AU - Eslam, Mohammed

AU - Sanyal, Arun J.

AU - George, Jacob

AU - Sanyal, Arun

AU - Neuschwander-Tetri, Brent

AU - Tiribelli, Claudio

AU - Kleiner, David E.

AU - Brunt, Elizabeth

AU - Bugianesi, Elisabetta

AU - Yki-Järvinen, Hannele

AU - Grønbæk, Henning

AU - Cortez-Pinto, Helena

AU - Fan, Jiangao

AU - Valenti, Luca

AU - Abdelmalek, Manal

AU - Romero-Gomez, Manuel

AU - Rinella, Mary

AU - Arrese, Marco

AU - Bedossa, Pierre

AU - Newsome, Philip N.

AU - Anstee, Quentin M.

AU - Jalan, Rajiv

AU - Bataller, Ramon

AU - Loomba, Rohit

AU - Sookoian, Silvia

AU - Sarin, Shiv K.

AU - Harrison, Stephen

AU - Kawaguchi, Takumi

AU - Wong, Vincent Wai Sun

AU - Ratziu, Vlad

AU - Yilmaz, Yusuf

AU - Younossi, Zobair

PY - 2020/5

Y1 - 2020/5

N2 - Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. Although pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge, and metabolic (dysfunction) associated fatty liver disease “MAFLD” was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and subphenotype the disease to accelerate the translational path to new treatments.

AB - Fatty liver associated with metabolic dysfunction is common, affects a quarter of the population, and has no approved drug therapy. Although pharmacotherapies are in development, response rates appear modest. The heterogeneous pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and definitions necessitate a reappraisal of nomenclature to inform clinical trial design and drug development. A group of experts sought to integrate current understanding of patient heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide suggestions on terminology that more accurately reflects pathogenesis and can help in patient stratification for management. Experts reached consensus that NAFLD does not reflect current knowledge, and metabolic (dysfunction) associated fatty liver disease “MAFLD” was suggested as a more appropriate overarching term. This opens the door for efforts from the research community to update the nomenclature and subphenotype the disease to accelerate the translational path to new treatments.

KW - Heterogeneity

KW - MAFLD

KW - Metabolic

KW - Nomenclature

UR - http://www.scopus.com/inward/record.url?scp=85079861644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079861644&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2019.11.312

DO - 10.1053/j.gastro.2019.11.312

M3 - Article

C2 - 32044314

AN - SCOPUS:85079861644

SN - 0016-5085

VL - 158

SP - 1999-2014.e1

JO - Gastroenterology

JF - Gastroenterology

IS - 7

ER -

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this